Reports
Sale
Global Glioblastoma Multiforme Treatment Market Size, Share, Trends, Report, Forecast: By Therapy: Chemotherapy, Radiation Therapy, Other Treatments; By End User: Hospitals, Ambulatory, Services; Regional Analysis; Regulatory Framework; Patent Analysis; Grants Analysis; Clinical Trials Analysis; Supplier Landscape; 2024-2032
Global Glioblastoma Multiforme Treatment Market Outlook
The global glioblastoma multiforme treatment market size was valued at USD 2.49 billion in 2023, driven by the increasing incidence of brain tumours across the globe. The market size is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032 to achieve a value of USD 5.15 billion by 2032.
Glioblastoma Multiforme Treatment: Introduction
Glioblastoma (GBM), commonly known as a grade IV astrocytoma, is an aggressive brain tumour that grows quickly. GBMs can develop from lower grade astrocytomas or develop from new brain tumours. The cerebral hemispheres of adults, particularly the frontal and temporal lobes, are where GBM develops most frequently. GBM is a deadly brain cancer that, if left untreated, can cause death in as little as six months.
Technologically advanced imaging techniques can be used to accurately pinpoint the location of brain tumours, such as computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI). Glioblastoma multiforme is often treated with surgery to remove as many tumours as feasible without harming the surrounding healthy brain tissue, then by radiation and chemotherapy. Most of the time, a craniotomy is used by surgeons to access the tumor site. The current standard of care for this illness is chemotherapy using the medication temozolomide. There are some types of brain tumours that are treated with temozolomide.
Global Glioblastoma Multiforme Treatment Market Analysis
The global market for glioblastoma multiforme treatment is witnessing significant growth due to the increasing focus towards developing better treatment options for patients which are affordable and convenient. The increasing number of approvals to conduct clinical studies to observe the complications associated with the condition and finding effective solutions are also influencing the market growth. These increasing approvals are directly contributing to the rise in number of clinical studies, providing hefty opportunities to develop and produce effective drugs for key players in the market especially cancer chemotherapy-based companies, further propelling the glioblastoma multiforme treatment market growth.
The increasing advancement in clinical imaging technologies such as computerized tomography (CT scan), and magnetic resonance imaging MRI are also enhancing the diagnosis process for glioblastoma multiforme with accuracy. The increasing contribution by the regional and state governments in the form of taking multiple initiatives to make sure that the treatment for such medical conditions is more accessible and affordable for everyone is also a major trend in the market. Due to the approvals followed by successful completion of clinical trials, pharmaceutical companies and other key players are constantly launching new, improved products and drugs that are helpful in curing glioblastoma multiforme, further boosting the global glioblastoma multiforme treatment market expansion.
Additionally, the FDA has approved the initiation of conducting a phase 2 clinical trial associated with assessing the safety and efficacy of azeliragon (previously TTP488) in patients with newly diagnosed unmethylated glioblastoma (GBM). Azeliragon is a pill which is taken once-a-day and administered orally. In January 2024, azeliragon was granted an orphan drug designation from the FDA for the treatment of GBM.
Global Glioblastoma Multiforme Treatment Market Segmentations
Market Breakup by Therapy
- Chemotherapy
- Radiation Therapy
- Other Treatments
Market Breakup by End User
- Hospitals
- Ambulatory Services
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Glioblastoma Multiforme Treatment Market Overview
The growth of the market is driven by the increasing burden of geriatric population, as people aged 60 and above are more susceptible to glioblastoma multiforme. Brain and other nervous system cancer is the tenth leading cause of death for men and women globally. The increasing incidence of brain tumours is primarily driving the demand for treatment. The increasing research studies, observations, and clinical trials about finding the potential of some drugs, such as Azeliragon, in the application against glioblastoma multiforme treatment are some major factors escalating the global glioblastoma multiforme treatment market development. The increasing approval for novel therapy and combination therapy for the treatment of glioblastoma multiforme is also driving the market growth.
North America is expected to lead the market throughout forecast period of 2024-2032. According to data statistics released by the American Society of Clinical Oncology (ASCO), nearly 24,810 adults (14,280 men and 10,530 women) are expected to be diagnosed with primary cancerous tumours of the brain and spinal cord in United States. The increase in new cancer cases associated with brain tumour will be responsible for increased research and development activities in the region and increase in manufacturing of drugs by the key players are also expected to drive the market growth.
Additionally, in 2024, it is predicted that primary cancerous brain and CNS tumours will be the leading cause of 18,990 deaths (11,020 men and 7,970 women). A projected 251,329 people worldwide passed away from primary CNS and brain tumours in 2020. For those under the age of 15, the relative 5-year survival rate is almost 75%. The relative 5-year survival rate for those aged 15 to 39 is quite close to 72%. For those over the age of 40, the 5-year relative survival rate is 21%.
Glioblastoma Multiforme Treatment Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Arbor Pharmaceuticals
- Bristol-Myers Squibb
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Sun Pharmaceutical Industries Ltd.
- Lanthen Pharmaceutical
- Pfizer Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Glioblastoma Multiforme Treatment Market Overview
3.1 Global Glioblastoma Multiforme Treatment Market Historical Value (2017-2023)
3.2 Global Glioblastoma Multiforme Treatment Market Forecast Value (2024-2032)
4 Global Glioblastoma Multiforme Treatment Market Landscape
4.1 Global Glioblastoma Multiforme Treatment: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Glioblastoma Multiforme Treatment: Product Landscape
4.2.1 Analysis by Drugs
4.2.2 Analysis by Therapy
5 Global Glioblastoma Multiforme Treatment Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Glioblastoma Multiforme Treatment Market Segmentation
6.1 Global Glioblastoma Multiforme Treatment Market by Therapy
6.1.1 Market Overview
6.1.2 Chemotherapy
6.1.3 Radiation Therapy
6.1.4 Other Treatments
6.2 Global Glioblastoma Multiforme Treatment Market by End User
6.2.1 Market Overview
6.2.2 Hospitals
6.2.3 Ambulatory Services
6.3 Global Glioblastoma Multiforme Treatment Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Glioblastoma Multiforme Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Glioblastoma Multiforme Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Glioblastoma Multiforme Treatment Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Glioblastoma Multiforme Treatment Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Glioblastoma Multiforme Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Arbor Pharmaceuticals
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Bristol-Myers Squibb
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Eli Lilly and Company
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 F. Hoffmann-La Roche Ltd
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Merck & Co. Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Sun Pharmaceutical Industries Ltd.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Lanthen Pharmaceutical
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Pfizer Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Amgen Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Teva Pharmaceutical Industries Ltd.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2.49 billion in 2023, driven by the increasing geriatric population.
The market is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032, likely to reach a market value of USD 5.15 billion by 2032.
The increase prevalence of brain disorders and increasing approvals of drugs and clinical trials are major factors driving the market growth.
The increasing research and development activities to develop advanced and new technologies and drugs to treat the patient suffering from glioblastoma multiforme is a major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Different types of therapies include chemotherapy and radiation therapy, and other treatments.
The end users in the market include hospitals and ambulatory services.
Key players involved in the market are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Lanthen Pharmaceutical.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER